1. Introduction {#sec1-ijms-21-00665}
===============

According to studies conducted over the last half century, nearly all cells on earth produce exosomes or exosome-like particles consisting of a lipid bilayer membrane \[[@B1-ijms-21-00665]\]. The shedding of exosomes is an evolutionarily well-conserved phenomenon found in all biological kingdoms \[[@B1-ijms-21-00665]\]. The discovery of exosomes occurred in the 1940s and platelet-derived particles in normal plasma were first reported in 1946 \[[@B2-ijms-21-00665]\] followed by a re-description as platelet dust in 1967 \[[@B3-ijms-21-00665]\]. However, exosomes received little attention for several decades because they were regarded as cellular garbage bins \[[@B4-ijms-21-00665]\]. In the mid-2000s, important discoveries regarding exosomes changed this trend. In 2007, the transfer of genetic materials such as mRNAs and miRNAs in exosomes was reported \[[@B5-ijms-21-00665]\]. Research on exosomes has been increased explosively since then, with more than 3000 papers published annually in 2018 and 2019 ([Figure 1](#ijms-21-00665-f001){ref-type="fig"}) \[[@B1-ijms-21-00665],[@B2-ijms-21-00665],[@B4-ijms-21-00665],[@B5-ijms-21-00665],[@B6-ijms-21-00665],[@B7-ijms-21-00665],[@B8-ijms-21-00665],[@B9-ijms-21-00665],[@B10-ijms-21-00665],[@B11-ijms-21-00665],[@B12-ijms-21-00665],[@B13-ijms-21-00665],[@B14-ijms-21-00665],[@B15-ijms-21-00665],[@B16-ijms-21-00665],[@B17-ijms-21-00665],[@B18-ijms-21-00665],[@B19-ijms-21-00665],[@B20-ijms-21-00665],[@B21-ijms-21-00665],[@B22-ijms-21-00665]\]. Exosomes, ranging 100--200 nm, from stem cells were reported to mediate the paracrine therapeutic effects of stem cells \[[@B6-ijms-21-00665]\]. Exosomes are important mediators of signal transfer in both multicellular and unicellular organisms. They are also important signaling mediators across species \[[@B14-ijms-21-00665],[@B23-ijms-21-00665]\]. In addition to basic research, medical and healthcare industrial applications of exosomes for the development of therapeutics, drug delivery vehicles, and liquid biopsies are rapidly progressing \[[@B24-ijms-21-00665],[@B25-ijms-21-00665],[@B26-ijms-21-00665]\].

2. Exosomes {#sec2-ijms-21-00665}
===========

2.1. Exosomes and Extracellular Vesicles {#sec2dot1-ijms-21-00665}
----------------------------------------

Extracellular vesicles (EVs) are lipid bilayered vesicles shed by cells. Three major types of EVs have been characterized according to their biogenesis: (1) exosomes are produced through the most complex process; specifically, inward budding of the cellular membrane results in the formation of early endosomes. Another inward budding of the early endosomal membrane results in multivesicular bodies (MVBs). Finally, fusion of MVBs with the plasma membrane sheds exosomes toward the extracellular space. The diameter of exosomes ranges from 30 to 200 nm; (2) microvesicles are produced from simple outward budding of the plasma membrane. The size of microvesicles are known to be from 100 or 200 to 1000 nm; and (3) apoptotic bodies are produced as a result of apoptotic cell death \[[@B27-ijms-21-00665]\]. The apoptotic bodies are the largest type of EVs with size from 500 to 2000 nm in diameter.

Since apoptotic bodies are byproducts of cell death, numerous attempts to develop EV-based therapeutics have focused on exosomes and microvesicles. Especially, exosomes are widely accepted as next generation therapeutics due to the extensive investigation of potential applications \[[@B28-ijms-21-00665],[@B29-ijms-21-00665]\]. As mentioned, the size ranges of exosomes and microvesicles overlap and it is difficult to differentially isolate these EVs according to their size \[[@B30-ijms-21-00665],[@B31-ijms-21-00665],[@B32-ijms-21-00665]\]. Recently, an alternative term, small extracellular vesicles (sEVs), was proposed to refer to EVs with diameters smaller than 200 nm \[[@B21-ijms-21-00665]\]. In this review, we refer to these smaller EVs as exosomes.

Specific markers of exosomes have been reported: ALIX and TSG101 are well-established markers of exosomes, and tetraspanins such as CD9, CD63, and CD81 are specific markers on the exosomal membrane. Additionally, exosomes contain a variety of specific proteins depending on their cells of origin \[[@B31-ijms-21-00665]\]. Interestingly, it has been reported that exosomes derived from mesenchymal stem cells (MSCs) or HEK 293T cells do not contain class I and class II human major histocompatibility complex (MHC) proteins or co-stimulatory molecules such as CD80 and CD86. The absence of these proteins on the exosomal surface suggests no immune rejection can be expected for allogeneic therapeutics \[[@B32-ijms-21-00665],[@B33-ijms-21-00665],[@B34-ijms-21-00665],[@B35-ijms-21-00665]\]. Exosomes derived from stem cells are actively being developed as a cell-free therapy because they recapitulate the functions of stem cells such as repair, regeneration, anti-inflation, and immune modulation without the limitations and risks of stem cells themselves \[[@B30-ijms-21-00665],[@B31-ijms-21-00665],[@B36-ijms-21-00665],[@B37-ijms-21-00665]\]. As an example, exosomes derived from MSCs have therapeutic effects on various diseases including myocardial infarction \[[@B6-ijms-21-00665],[@B38-ijms-21-00665]\], CCl4-induced liver injury \[[@B39-ijms-21-00665]\], graft-versus-host disease (GvHD) \[[@B20-ijms-21-00665]\], acute and chronic kidney injury \[[@B40-ijms-21-00665]\], and atopic dermatitis \[[@B34-ijms-21-00665],[@B41-ijms-21-00665]\].

The size of exosomes enables their safe systemic administration through multiple routes without the risk of embolism compared to cell-based therapy \[[@B42-ijms-21-00665]\]. There is also a low risk of tumorigenesis since exosomes cannot replicate themselves \[[@B43-ijms-21-00665]\]. In addition, the use of exosomes would avoid various issues related to cell therapy such as the inability to sterilize the cells, short shelf-life, and limited quality control (QC) before release \[[@B41-ijms-21-00665],[@B44-ijms-21-00665]\]. A couple of studies have also reported that exosomes from MSCs and HEK 293T did not cause toxicity in vivo or in vitro \[[@B44-ijms-21-00665],[@B45-ijms-21-00665],[@B46-ijms-21-00665],[@B47-ijms-21-00665],[@B48-ijms-21-00665]\]. A recent study suggested that long-term repetitive injection of exosomes does not induce toxicity \[[@B45-ijms-21-00665]\]. Nano-sized exosomes may reach and accumulate in additional tissues beyond the tissues of therapeutic interest through systemic administration. Therefore, analysis of the biodistribution following administration through the intended route is a prerequisite for the development of exosome-based therapeutics.

2.2. Technologies for Isolation of Exosomes {#sec2dot2-ijms-21-00665}
-------------------------------------------

The most important hurdle to overcome for exosome-based therapy is development of the proper technologies for large scale isolation of exosomes \[[@B49-ijms-21-00665]\]. Exosomes from different sources have been isolated with various experimental methods such as differential ultracentrifugation (UC), density gradient ultracentrifugation (DGUC), ultrafiltration (UF), size exclusion chromatography (SEC), precipitation, and tangential flow filtration (TFF) \[[@B50-ijms-21-00665],[@B51-ijms-21-00665]\]. According to a recent report, UC is the most widely used method to isolate exosomes from conditioned media of MSCs \[[@B24-ijms-21-00665]\]. Commercial kits, which are mostly based on the precipitation of proteins, were the second choice for exosome isolation among the 126 papers analyzed in a recent report \[[@B24-ijms-21-00665]\].

Among various methods, TFF has been proposed as the ideal method for industrial manufacture of exosomes \[[@B51-ijms-21-00665]\]. Compared to other methods, which have limited compliance with good manufacturing practice (GMP), the availability of GMP-compliant TFF systems may also result in validated process control and GMP documents \[[@B50-ijms-21-00665]\]. Methods based on UC have a risk of producing exosomes with co-precipitated contaminants and functional loss due to exosome aggregation caused by high pressure during centrifugation. The media used in DGUC may inhibit the function of exosomes \[[@B51-ijms-21-00665]\]. Commercial kits based on protein precipitation are widely used in many academic labs. However, the additives used for precipitation (e.g., polyethylene glycol (PEG)) may inhibit the biological functions of exosomes. Although SEC has the advantage of removing proteins smaller than exosomes, a low recovery rate and the potential loss of exosome function were reported \[[@B51-ijms-21-00665]\]. In principle, SEC cannot distinguish exosomes from non-exosomal particles with similar sizes. Recent reports revealed the functional importance of proteins associated with the surface of exosomes \[[@B52-ijms-21-00665],[@B53-ijms-21-00665]\]. These results suggest that careful selection of the proper methods is important to isolate functional exosomes without the loss of these surface-associated proteins.

2.3. Quality Control of Exosomes {#sec2dot3-ijms-21-00665}
--------------------------------

The QC of isolated exosomes is of importance for both reproducible research and the development of therapeutics. In an international effort to establish standards for exosome analysis, the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV 2018) was suggested through a series of publications \[[@B21-ijms-21-00665],[@B54-ijms-21-00665],[@B55-ijms-21-00665]\]. Many studies also reported on the GMP production of exosomes for the development of therapeutics with suggested release criteria \[[@B45-ijms-21-00665],[@B50-ijms-21-00665],[@B56-ijms-21-00665],[@B57-ijms-21-00665],[@B58-ijms-21-00665],[@B59-ijms-21-00665],[@B60-ijms-21-00665],[@B61-ijms-21-00665]\]. The worldwide market for exosome-based therapy is expected to grow from 5 million USD in 2016 to 10.0 million USD in 2021, with a compound annual growth rate (CAGR) of 14.9% \[[@B62-ijms-21-00665]\]. In terms of regulation, fast-track approval of exosome therapeutics by regulatory authorities in Korea, Italy, and China is expected \[[@B62-ijms-21-00665]\]. The Korea Ministry of Food and Drug Safety (MFDS) published the Guideline on Quality, Non-clinical and Clinical Assessment of Extracellular Vesicles Therapy Products in 2018 \[[@B22-ijms-21-00665]\]. As shown in [Table 1](#ijms-21-00665-t001){ref-type="table"}, most of the criteria in the MISEV 2018 and the MFDS Guideline are quite similar. The MFDS Guideline also includes guides for the characterization of starting materials, methods for the production, isolation, and characterization of exosomes, stability testing, the consideration of non-clinical studies, toxicological evaluation, and the considerations of clinical studies.

3. Analysis of Exosomes Biodistribution {#sec3-ijms-21-00665}
=======================================

3.1. Bioimaging Modalities {#sec3dot1-ijms-21-00665}
--------------------------

Various modalities, such as bioluminescence imaging (BLI), nuclear, fluorescence, and magnetic resonance imaging (MRI) \[[@B63-ijms-21-00665],[@B64-ijms-21-00665],[@B65-ijms-21-00665]\], have been used for in vivo imaging ([Table 2](#ijms-21-00665-t002){ref-type="table"}). In general, BLI is known to have the highest sensitivity and high signal-to-noise ratio while nuclear imaging has the highest penetration \[[@B63-ijms-21-00665]\]. However, BLI with luciferase requires additional administration of substrates for luciferase and is limited by the low spatial and temporal resolution. Nuclear imaging requires hazardous radioisotopes with low spatial resolution and high cost. Fluorescence imaging with near infrared (NIR) fluorescent dyes is limited by the spatial and temporal resolution. Fluorescence imaging using fluorescent proteins (FP) has the highest spatial resolution. However, the low penetration of FP fluorescence does not allow noninvasive in vivo imaging. MRI has high penetration with high spatial and temporal resolution but is limited by low sensitivity and high cost.

3.2. Labeling Methods for Exosomes {#sec3dot2-ijms-21-00665}
----------------------------------

For in vivo imaging, exosomes have to be labeled with probes using proper methods. Methods for labeling probes include covalent binding, genetic modification, membrane integration, encapsulation (or internalization), and metabolic labeling ([Table 3](#ijms-21-00665-t003){ref-type="table"}).

### 3.2.1. Covalent Binding {#sec3dot2dot1-ijms-21-00665}

Covalent binding can be used to label exosomes by reacting them with probes that have functional moieties. Due to the covalent bonding, labeled probes tightly bind to exosomes with minimal dissociation. However, nonspecific exosomal proteins may also be labeled when using this method. Additionally, the labeling of exosomal surface proteins may affect their function and/or structure resulting in altered interactions of the exosomes with the target cells. It was recently reported that the modification of surface proteins altered the biodistribution of exosomes \[[@B66-ijms-21-00665]\]. According to this report, treatment of glycosidase with exosomes resulted in a slight increase in the lung distribution of exosomes in mice compared to the distribution of untreated exosomes. However, it is necessary to further explore this finding with a large number of animals to obtain more statistically significant results since only three mice per group were used in the study. Another study performed without covalent binding suggested that labeling exosomes with lipophilic dyes also slightly changes the biodistribution of exosomes. The researchers labeled exosomes containing luciferase, with a lipophilic fluorescent dye and compared the biodistribution of the exosomes with and without the lipophilic dyes \[[@B67-ijms-21-00665]\]. The exosomes without the lipophilic dye, accumulated in the organs in the following order: lung \> liver \> spleen \> kidney. On the contrary, the exosomes with the lipophilic dye accumulated in the organs in the following order: liver \> lung and spleen. Taken together, it is necessary to develop a method to analyze the effect of exosome surface modification.

### 3.2.2. Surface Modification {#sec3dot2dot2-ijms-21-00665}

Surface modification of exosomes can be avoided by genetic modification to load probe proteins into exosomes. To date, luciferase proteins are mostly used for genetic modification ([Table 4](#ijms-21-00665-t004){ref-type="table"}). However, genetic modification may change the property of cells and even exosomes. Uneven loading of probe proteins is another issue that needs to be addressed \[[@B68-ijms-21-00665],[@B69-ijms-21-00665]\].

### 3.2.3. Membrane Integration {#sec3dot2dot3-ijms-21-00665}

The most widely used labeling method for exosomes is membrane integration of lipophilic fluorescent dyes. This method is simple and easy, but carries the risk of exosome aggregation \[[@B65-ijms-21-00665]\]. Another issue with lipophilic dyes is that they can label both lipoproteins and lipid micelles. Lipophilic dyes have been widely used to analyze the biodistribution of cells for the development of cell-based therapies. A study reported that there was no transfer of lipophilic dyes such as PKH67 or Dil from labeled to unlabeled cells in co-culture conditions \[[@B70-ijms-21-00665]\]. These results suggest that there is a low risk of background signals resulting from the transfer of lipophilic dyes released from exosome membranes to the target tissue or cells. On the other hand, the long in vivo half-life of lipophilic dyes may cause pseudo signals after the clearance of exosomes \[[@B65-ijms-21-00665]\]. The in vivo half-life of PKH2 and PKH26 was reported to be 12 days and more than 100 days, respectively \[[@B71-ijms-21-00665]\]. Dialkylcarbocyanine dyes, such as DiD, Dil, DiO, and DiR, are also widely used. The in vivo half-life of DiR is known to be approximately 4 weeks \[[@B72-ijms-21-00665]\]. Taken together, it is necessary to include a control containing lipophilic dyes alone \[[@B45-ijms-21-00665]\]. Another potential issue with the use of lipophilic dyes is the formation of micelles in the liquid because of the lipophilic nature of the dyes \[[@B73-ijms-21-00665]\]. When PKH26 or CM-Dil was incubated in phosphate-buffered saline (PBS) without exosomes, there were detectable levels of particles. On the contrary, in our studies, no detectable particles were observed when PKH dyes were incubated in the PBS without exosomes. In addition, no detectable changes in particle numbers were observed when PKH dyes were reacted with exosomes at the appropriate concentration (unpublished observation). Again, it is important to include a negative control that consists of the lipophilic dyes in the same buffer without exosomes. Since removal of free unlabeled dyes is a prerequisite, it is also important to process this negative control using with same removal method.

### 3.2.4. Encapsulation {#sec3dot2dot4-ijms-21-00665}

Encapsulation can be applied to label exosomes, while avoiding surface modification. However, electroporation may cause the aggregation of exosomes or structural distortion of the membrane, resulting in fused exosomes \[[@B65-ijms-21-00665]\]. When lipophilic materials are used for encapsulation, it is difficult to exclude the possibility of sustained release of internalized probes from the exosomes. It is expected that uneven distribution of transporter proteins on the exosome membrane may cause uneven loading of probes when a transporter protein is utilized for the encapsulation of probes. The expression of a specific transporter protein is also limited by the cell types.

### 3.2.5. Metabolic Labeling {#sec3dot2dot5-ijms-21-00665}

Metabolic labeling of exosomes is achievable with the addition of specific substances during the cell culture process. After the isolation of metabolically labeled exosomes, covalent binding of the probes can be achieved with click chemistry \[[@B74-ijms-21-00665]\]. However, the addition of extra substances during cell culture may cause changes in the characteristics of the cells or exosomes.

3.3. Analysis of Biodistribution of Exosomes in Literature {#sec3dot3-ijms-21-00665}
----------------------------------------------------------

We analyzed 29 published papers that reported biodistribution studies of different exosomes or EVs ([Table 4](#ijms-21-00665-t004){ref-type="table"}). The most widely used labeling method was membrane integration of lipophilic dyes followed by covalent binding, encapsulation (or internalization), and genetic engineering ([Figure 2](#ijms-21-00665-f002){ref-type="fig"}). Only one paper described metabolic labeling.

### 3.3.1. Labeling Methods {#sec3dot3dot1-ijms-21-00665}

All four papers involving genetic engineering described the use of luciferases. No publication was reported using fluorescent proteins ([Table 4](#ijms-21-00665-t004){ref-type="table"}). As discussed, the low penetration of fluorescence is not suitable for noninvasive in vivo imaging ([Table 2](#ijms-21-00665-t002){ref-type="table"}). Genetic engineering may cause changes in the characteristics of host cells or even exosomes. When genetically modified cells are used to produce labeled exosomes, the possibility of differences in the characteristics of labeled exosomes for biodistribution analysis and unlabeled exosomes for therapeutic use cannot be excluded. On the other hand, genetically labeled exosomes have an advantage in comparing their in vivo distribution with and without additional labeling. Especially, genetically labeled exosomes can be utilized to monitor the effects of surface modifications, such as covalent binding or membrane integration, which may cause structural or functional changes in the membranes of exosomes \[[@B67-ijms-21-00665]\].

Labeling of exosomes by encapsulation has been performed with various labeling probes such as radioisotopes, nanoparticles, and fluorescent dyes ([Table 4](#ijms-21-00665-t004){ref-type="table"}). Passive loading of probes is frequently used. An interesting example of active loading of probes is the use of transporter proteins on the membrane of exosomes. A study reported the encapsulation of glucose-coated gold nanoparticles by the GLUT1 glucose transporter on the exosomal membrane \[[@B75-ijms-21-00665]\]. Additional transporters are expected to be available for the specific encapsulation of probes in exosomes obtained from different sources with the advancement of research. However, the distribution or abundance of transporter proteins on the exosomal membrane may cause the uneven loading of proteins. Sonication was also employed to encapsulate probes in exosomes \[[@B76-ijms-21-00665]\]. However, sonication may cause distortion or damage to the exosomal membrane, eventually affecting the biodistribution of exosomes. Additionally, superparamagnetic iron oxide (SPIO) nanoparticles have been used to label exosomes through the transfection of exosome-producing cells \[[@B75-ijms-21-00665]\]. It is important to recognize that the loading amount of nanoparticles is restricted by their size. The hydrodynamic radius of SPIO nanoparticles in a previous report \[[@B75-ijms-21-00665]\] was 62 nm (<https://www.magneticinsight.com/wp-content/uploads/2016/05/VivoTrax_datasheet.pdf>). Since the diameter of exosomes in the study is around 100 nm \[[@B75-ijms-21-00665]\], the loading efficiency of SPIO nanoparticles in exosomes seems to be limited.

Among the 29 papers reviewed, eight papers reported the labeling of exosomes by covalent binding to probes. The most commonly used labeling modality for covalent binding was radioisotope labeling (five out of eight) ([Table 4](#ijms-21-00665-t004){ref-type="table"}). Fluorescent dyes (three out of eight) were also used for covalent binding. The advantage of covalent binding is the low risk of pseudo-positive signals caused by the spontaneous release of probes without covalent bonds. However, careful analysis is required since modification of surface proteins by the covalent binding of probes may change the interaction of exosomes and their target tissues or cells \[[@B73-ijms-21-00665],[@B76-ijms-21-00665]\].

The most widely used labeling method is the membrane integration of lipophilic fluorescent dyes ([Figure 2](#ijms-21-00665-f002){ref-type="fig"}, left). Fifty percent of the studies evaluated used the membrane integration strategy with lipophilic fluorescent dyes ([Table 4](#ijms-21-00665-t004){ref-type="table"}). For membrane integration, fluorescent probes were overwhelmingly selected over other methods ([Figure 2](#ijms-21-00665-f002){ref-type="fig"}, right). DiR was the most frequently used lipophilic fluorescent dye ([Figure 3](#ijms-21-00665-f003){ref-type="fig"}). DiR is a dialkylcabarbocyanine with NIR fluorescence which is ideal for in vivo imaging since it has low absorption by biological materials \[[@B98-ijms-21-00665]\]. The FDA-approved NIR dye Indocyanine Green (ICG) is also able to label exosomes \[[@B99-ijms-21-00665],[@B100-ijms-21-00665]\]. A potential issue is the possibility of lipophilic dyes forming micelles in the liquid \[[@B73-ijms-21-00665]\]. Therefore, it is of utmost importance to compare the number of particles before and after labeling with lipophilic dyes. In addition, it is necessary to include a proper negative control containing the appropriate amount of lipophilic dye \[[@B45-ijms-21-00665]\]. A buffer solution with lipophilic dyes incubated and processed using the same procedures employed for the exosomes with lipophilic dyes may also be a good negative control.

### 3.3.2. Characterization of Exosomes {#sec3dot3dot2-ijms-21-00665}

One unexpected finding is that many studies used exosomes or EVs without characterization. As mentioned earlier, QC of exosomes is essential for both reproducible basic exosome research and the development of exosome therapeutics. The ISEV also proposed minimal requirements in the MISEV2018 guidelines for the identification of exosomes by analyzing specific markers \[[@B21-ijms-21-00665]\]. Surprisingly, we found that approximately 40% of studies did not include the analysis of specific markers ([Figure 4](#ijms-21-00665-f004){ref-type="fig"}). Other than publications with exosome-like vesicles from microorganisms or exosome mimetics, 11 publications did not provide the results of specific marker analysis ([Table 4](#ijms-21-00665-t004){ref-type="table"}). Although the results of NTA or electron microscopic analysis were reported in some cases, these results are not sufficient to confirm the identity of the exosomes used in the studies. More importantly, analysis of specific markers is especially important to compare the properties of exosomes and analyze the recovery rate between before and after labeling.

### 3.3.3. Exosome Isolation Methods {#sec3dot3dot3-ijms-21-00665}

Selection of the appropriate isolation method is essential for the industrial development of exosome-based therapeutics \[[@B50-ijms-21-00665],[@B51-ijms-21-00665]\]. As shown in [Figure 5](#ijms-21-00665-f005){ref-type="fig"}, the dominant method for isolating exosomes is UC. This implies that UC is still the general method used to isolate exosomes in most academic settings, although the method is not ideal for the mass production of exosomes for the development of therapeutics. SEC was reported in only one publication \[[@B82-ijms-21-00665]\]. In a few studies, precipitation with commercial kits was used to isolate exosomes. The process should be carefully monitored to determine whether the additives used for precipitation such as PEG have adverse effects on the labeling or biodistribution of exosomes. Ideally, these additives should be removed from the final exosome products before administration to an experimental animal. One publication reported that there was no significant difference in the biodistribution of exosomes isolated using UC or SEC \[[@B93-ijms-21-00665]\].

Another important aspect to consider is the removal of excess unlabeled probes from labeled exosomes. UC was the most commonly used method for removing free probes in the studies evaluated ([Figure 6](#ijms-21-00665-f006){ref-type="fig"}). Interestingly, SEC was the second most frequently method for removing free probes. One drawback of SEC was the increase of sample volume with multiple fractions during the isolation process. To avoid this, methods based on the gel filtration (GF) principle are possible alternatives to conventional SEC. Commercial GF columns are already available to remove free probes by simple centrifugation without a significant increase in the sample volume \[[@B44-ijms-21-00665],[@B74-ijms-21-00665],[@B82-ijms-21-00665],[@B97-ijms-21-00665]\]. Precipitation methods were also used to remove free probes. Again, the possibility of adverse effects from the additives used for precipitation cannot be excluded without further steps to remove the additives.

### 3.3.4. Determination of Exosome Dose {#sec3dot3dot4-ijms-21-00665}

Determination of the exosome dose for biodistribution analysis is another essential factor. Since exosomes are composed of lipids, proteins, and nucleic acids, it is possible to determine the exosome dose from the total amounts of lipids, proteins, or nucleic acids, respectively. It is also possible to determine the exosome dose from the total number of particles \[[@B21-ijms-21-00665]\]. As shown in [Figure 7](#ijms-21-00665-f007){ref-type="fig"}, the most frequently used parameter for exosome dose determination was the amount of total proteins, followed by the number of particles. Parallel description of the amount of proteins and the number of particles was also reported in three publications as suggested by the ISEV in MISEV2018 \[[@B21-ijms-21-00665]\]. The range of total proteins was from 10 to 500 μg per animal and that of the number of particles was from 2.8 × 10^9^ to approximately 3.8 × 10^11^ particles per animal ([Table 4](#ijms-21-00665-t004){ref-type="table"}). Interestingly, all publications exclusively reported the use of mice for exosome biodistribution analysis. Recently, increasing evidence suggests that the use of zebrafish is a promising new approach to study in vivo physiology and pathology of exosomes \[[@B101-ijms-21-00665]\]. Indeed, the transparency and small size of the zebrafish embryo enables live whole-body imaging analysis for better understanding of biodistribution including exosome uptake and fate.

### 3.3.5. Routes of Administration {#sec3dot3dot5-ijms-21-00665}

For in vivo analysis of exosome distribution, intravenous (IV) injection of exosomes was the dominant (78%) administration route ([Figure 8](#ijms-21-00665-f008){ref-type="fig"}). Three publications used intraperitoneal injection as an alternative route. The administration of exosomes through intranasal, hock, subcutaneous, and retro-orbital venous sinus routes was rarely used. The most frequent accumulation tissues for exosomes after IV injection were reported as the liver, lung, spleen, and kidney ([Table 4](#ijms-21-00665-t004){ref-type="table"}). Although the modification of surface proteins such as glycosylation may have affected the in vivo distribution of exosomes in a few reports \[[@B66-ijms-21-00665],[@B67-ijms-21-00665]\], additional studies with more animals seems to be necessary for more accurate analysis. It was also reported that there was a difference in the biodistribution of exosomes according to the exosome-producing cells \[[@B68-ijms-21-00665]\]. Further studies will be needed to determine the significance of these findings.

3.4. Therapeutic Implication of Exosome Biodistribution {#sec3dot4-ijms-21-00665}
-------------------------------------------------------

As mentioned, the information on in vivo distribution of exosomes provides basis for prediction of dose and potential side effects. In addition, it also provides the clue for target tissues of specific therapeutic application. Several studies have already provided the relevance between biodistribution and therapeutic effects.

### 3.4.1. Natural Targeting Properties of Exosomes {#sec3dot4dot1-ijms-21-00665}

Tissue tropism is dependent on the surface composition of exosomes \[[@B102-ijms-21-00665]\]. Different integrin compositions determine the organotropism of exosomes derived from different tumors \[[@B103-ijms-21-00665]\]. Secreted proteins such as Wnt4 and TGF-β1 have been identified to be associated with exosomes \[[@B53-ijms-21-00665],[@B104-ijms-21-00665]\]. Wnt4-associated exosomes derived from thymic epithelial cells accumulated in the thymus of mice and this tropism was further enhanced by overexpression of Wnt4 in the originating cells, which might induce regeneration of thymus \[[@B87-ijms-21-00665]\]. More interestingly, EVs from *Helicobactor pyroli* was reported to preferentially accumulate in stomach and induce inflammatory responses \[[@B78-ijms-21-00665]\].

### 3.4.2. Tumor-Homing of Exosomes {#sec3dot4dot2-ijms-21-00665}

Tumor-homing exosomes could be exploited as targeting delivery vehicles. As an example, hypoxic cancer-homing exosomes, which were loaded with olaparib, demonstrated retarded tumor growth in xenograft mice \[[@B75-ijms-21-00665]\]. Interestingly, exosomes derived from MSCs (MSC-exosomes) have been reported to exhibit tumor-homing properties similar to those of MSCs \[[@B105-ijms-21-00665]\]. Human UC-MSC-exosomes were reported to accumulate in tumor of mouse osteosarcoma K7M2 cells in nude mice \[[@B86-ijms-21-00665]\]. These UC-MSC-exosomes reduced proliferation of human osteosarcoma 143B and mouse osteosarcoma K7M2 cells in vitro in a dose-dependent manner by inducing apoptosis. The tumor-homing of MSC-exosomes has been successfully adopted to deliver therapeutic miRNAs to reduce tumors in xenograft mice with patient-derived pancreatic cancer \[[@B45-ijms-21-00665]\], and syngeneic breast tumors in mice \[[@B90-ijms-21-00665]\]. Interestingly, beyond organotropism of tumor exosomes, generalized tropism of tumor exosomes toward neoplastic tissues from different types or species have also been reported \[[@B106-ijms-21-00665]\].

### 3.4.3. Accumulation of MSC-Exosomes in Damaged Tissues {#sec3dot4dot3-ijms-21-00665}

An interesting finding is that MSC-exosomes were preferentially accumulated in the kidneys of mice with glycerol-induced acute kidney injury compared to the distribution in normal mice \[[@B95-ijms-21-00665]\]. The application of MSCs as a cell-based therapy for acute or chronic kidney disease has been studied \[[@B107-ijms-21-00665]\]. MSC-exosomes have also been reported to be effective for kidney diseases in various animal models \[[@B108-ijms-21-00665]\]. Since MSCs are known to accumulate in damaged tissues through the interactions of receptors on the MSCs and target tissues \[[@B109-ijms-21-00665],[@B110-ijms-21-00665]\], it is highly probable that MSC-exosomes are also localized in damaged tissues due to these receptor interactions. Similarly, exosomes from endothelial progenitor cells showed accumulation in ischemic kidney to prevent ischemic injury through CXCR4--SDF-1α interaction \[[@B91-ijms-21-00665]\].

### 3.4.4. Tissue Targeting by Exosome Engineering {#sec3dot4dot4-ijms-21-00665}

In addition to natural cell-targeting abilities, it is also possible to engineer exosomes to target specific tissues or cells \[[@B102-ijms-21-00665]\]. PEGylation of exosomes resulted in targeted accumulation of exosomes derived from cardiosphere-derived cells in ischemic myocardium in mice \[[@B111-ijms-21-00665]\]. Targeted delivery of exosomes by genetic modification of their surface proteins has been also been reported: (1) brain targeting by rabies viral glycoprotein (RVG) peptide or RGD motif \[[@B19-ijms-21-00665],[@B112-ijms-21-00665]\]; and (2) tumor targeting by EGFR-specific nanobodies or HER2-specific single-chain variable fragments \[[@B113-ijms-21-00665]\]. Recently a peptide CP05, which binds CD63, was introduced as an anchor for homing moieties to change the biodistribution of exosomes \[[@B89-ijms-21-00665]\]. Engineered exosomes with tumor specificity could be also used to delivery chemotherapeutic agents to reduce tumors in vivo \[[@B76-ijms-21-00665]\]. In fact, exosomes are being developed as drug carriers since they are a natural-born delivery vehicle. A wide variety of therapeutic molecules can be delivered by exosomes, including small molecules \[[@B114-ijms-21-00665],[@B115-ijms-21-00665]\], anti-cancer drugs such as paclitaxel \[[@B116-ijms-21-00665]\] and doxorubicin \[[@B117-ijms-21-00665]\], and oncolytic viruses as well \[[@B116-ijms-21-00665],[@B118-ijms-21-00665],[@B119-ijms-21-00665]\].

4. Conclusions {#sec4-ijms-21-00665}
==============

Exosomes from different cell types have unique features according to their originating cell types and are being rapidly developed as therapeutic agents, drug delivery vehicles, and liquid biopsy markers. Exosomes derived from MSCs are attractive for next generation cell-free therapeutics since they recapitulate MSC capabilities of repair/regeneration, anti-inflammation, and immune modulation and overcome the potential risk and limitations of cell-based therapeutics.

Analysis of the biodistribution of exosomes is an essential step to determine the therapeutic dose and predict the potential side effects of exosomes. However, this is extremely challenging because of the nano-range of their sizes and complex nature of their composition. QC of produced exosomes is also extremely important to ensure reproducible results. Additionally, the labeling methods and analytical modalities are limited by the characteristics of exosomes produced by living cells. A growing number of studies and advances in the methods and modalities are expected to provide proper evaluation solutions for high quality exosomes therapeutics in the near future.

Conceptualization, Y.W.Y. and J.H.L.; writing---original draft preparation, Y.W.Y.; writing---review and editing, Y.W.Y., J.H.L., S.-Y.K., C.-G.P., D.H.H., S.R.P., J.Y., and B.S.C.; funding acquisition, Y.W.Y., S.-Y.K., and B.S.C.; supervision, B.S.C. All authors have read and agreed to the published version of the manuscript.

This study was partially supported by a grant (19172MFDS166) from the Ministry of Food and Drug Safety in 2019. This study was also partially supported by ExoCoBio Inc.

Y.W.Y. and B.S.C. are founders and stockholders of ExoCoBio Inc. Y.W.Y., J.H.L., D.H.H., S.R.P., J.Y., and B.S.C. are employees of ExoCoBio Inc.

AKI

acute kidney injury

BC

Breast cancer

BLI

bioluminescence imaging

BMSC

bone marrow stromal cell

BW

body weight

CAGR

compound annual growth rate

CV

cellular vesicle

CT

computed tomography

DGUC

density-gradient ultracentrifugation

DLS

dynamic light scattering

EPCs

endothelial progenitor cells

EVs

extracellular vesicles

FI

fluorescence intensity

FP

fluorescence protein

GMP

good manufacturing practice

GNP

gold nanoparticle

GvHD

Graft-versus-host disease

ICP-MS

inductively coupled plasma mass spectroscopy

IN

intranasal

ISEV

International Society for Extracellular Vesicles

IV

intravenous

IP

intraperitoneal

MDSCs

myeloid derived suppressor cells

MFDS

Ministry of Food and Drug Safety, Korea

MISEV

Minimal Information for Studies of Extracellular Vesicles

MHC

Major histocompatibility complex

MPI

magnetic particle imaging

MRI

magnetic resonance imaging

MSCs

mesenchymal stem/stromal cells

MVBs

multivesicular bodies

NA

not applicable

ND

not determined

NIR

near infrared

NR

nuclear imaging

NTA

nanoparticle tracking analysis

OMV

outer membrane vesicle

PEG

polyethylene glycol

PET

position-emission tomography

QCs

quality controls

RI

radioisotope

RLU

relative luminescence unit

ROVS

retro-orbital venous sinus

RPS

resistive pulse sensing

SC

subcutaneous

SEC

size exclusion chromatography

SPECT

single-photon emission computed tomography

SPIO

superparamagnetic iron oxide

TEI

total exosome isolation reagent

TFF

tangential flow filtration

UC

ultracentrifugation

UC-MSC

umbilical cord MSC

UF

ultrafiltration

![Trends of publications and major discoveries regarding exosomes. The number of publications was retrieved with a PubMed search using the keywords exosomes, exosome, extracellular vesicles, extracellular vesicle, and platelet-derived particles on 17 October 2019.](ijms-21-00665-g001){#ijms-21-00665-f001}

![Labeling methods and probes used for labeling exosomes.](ijms-21-00665-g002){#ijms-21-00665-f002}

![Fluorescent dyes used in biodistribution analysis of exosomes.](ijms-21-00665-g003){#ijms-21-00665-f003}

![Status of analysis for specific markers for exosomes or extracellular vesicles (EVs).](ijms-21-00665-g004){#ijms-21-00665-f004}

![Isolation methods of exosomes in literature of exosome biodistribution.](ijms-21-00665-g005){#ijms-21-00665-f005}

![Methods to remove unlabeled probes from labeled exosomes.](ijms-21-00665-g006){#ijms-21-00665-f006}

![Determination of exosome dose in biodistribution. Abbreviations: Protein, total amount of proteins; number, total number of particles; P + N, total amount of proteins with total number of particles; Lipid, total amount of lipids.](ijms-21-00665-g007){#ijms-21-00665-f007}

![Administration route of exosomes for biodistribution analysis.](ijms-21-00665-g008){#ijms-21-00665-f008}

ijms-21-00665-t001_Table 1

###### 

Comparison of Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) and the Korea Ministry of Food and Drug Safety (MFDS) Guideline.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  QC Criteria                          MISEV2018 Recommendation                                                                             MFDS Guideline (2018)                                                                       Examples
  ------------------------------------ ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Exosome Number (or quantification)   Global quantification by at least two methods: protein amount, particle number, lipid amount, etc.   Number of vesicles (or particles) and total protein amount or others                        Nanoparticle tracking analysis (NTA)\
                                                                                                                                                                                                                                        Protein quantification

  Exosome Size                         RPS, NTA, DLS, etc.                                                                                  NTA, DLS, RPS, fluorescence correlation spectroscopy, etc.                                  NTA

  Identity                             Protein markers;\                                                                                    At least semi-quantitative method to detect proteins, RNAs, or lipids enriched in exosome   Western blot: CD9, CD63, CD81, ALIX, TSG101\
                                       Phospholipids                                                                                                                                                                                    FCM: CD9, CD63, CD81, and more\
                                                                                                                                                                                                                                        ELISA

  Purity                               Ratios of two quantification figures (e.g., protein:particle)\                                       For proteins which are not expected to enrich in exosomes;\                                 ELISA for Calnexin or GM130\
                                       Assessment of absence of expected contamination                                                      For process impurities: serum albumin, antibiotics, etc.                                    ELISA for impurities

  Potency Assays                       Dose-response assessment                                                                             Biological assay which can represent MoA                                                    Various methods: immune-modulation, proliferation, collagen, etc.

  Others                               not mentioned                                                                                        Mycoplasma, Sterility, Endotoxin, and Virus tests                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-21-00665-t002_Table 2

###### 

Comparison of bioimaging modalities.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Modality                                                                         Examples     Pros                                              Cons
  -------------------------------------------------------------------------------- ------------ ------------------------------------------------- ---------------------------------------------------------------------
  Bioluminescence Imaging \[[@B63-ijms-21-00665],[@B64-ijms-21-00665]\]            Luciferase   Highest sensitivity (10^−15^−10^−17^ mole/L)\     Substrate needed\
                                                                                                Medium cost\                                      Medium penetration (mm−cm)\
                                                                                                High signal-to-noise (compared to fluorescence)   Low spatial resolution (mm)\
                                                                                                                                                  Low temporal resolution (sec−min)

  Nuclear Imaging\                                                                 99 mTc       Highest penetration (m)\                          Hazardous\
  (PET/SPECT) \[[@B63-ijms-21-00665],[@B64-ijms-21-00665],[@B65-ijms-21-00665]\]                High sensitivity (10^−10^−10^−12^ mole/L)\        Low spatial resolution (mm)\
                                                                                                Medium temporal resolution (10 s−min)             High cost

  NIR Fluorescence Imaging \[[@B63-ijms-21-00665],[@B64-ijms-21-00665]\]           DiR          Medium penetration (mm−cm)\                       Low spatial resolution (mm)\
                                                                                                Medium sensitivity (10^−9^−10^−12^ mole/L)\       Low temporal resolution (s−min)
                                                                                                Low cost                                          

  Fluorescent Protein Imaging \[[@B63-ijms-21-00665],[@B64-ijms-21-00665]\]        GFP          Highest spatial resolution (nm)\                  Lowest penetration (mm): does not allow noninvasive in vivo imaging
                                                                                                Medium sensitivity                                

  Magnetic Resonance Imaging (MRI) \[[@B63-ijms-21-00665],[@B64-ijms-21-00665]\]   SPIO         Highest penetration (m)\                          Lowest sensitivity (10^−3^−10^−5^ mole/L)\
                                                                                                High spatial resolution (μm)\                     High cost
                                                                                                Highest temporal resolution (min−h)               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-21-00665-t003_Table 3

###### 

Comparison of labeling methods.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Labeling Methods                      Pros                                           Cons                                                                                               Reference
  ------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------- -----------------------------------------------
  Covalent biding                       Tight binding of probes to proteins            Cannot distinguish between exosomes vs. non-exosome proteins\                                      \[[@B66-ijms-21-00665]\]
                                                                                       May change membrane protein functions which affect the interaction of exosomes with target cells   

  Genetic modification                  Can avoid surface modification                 Genetic change of cells may change the property of cells and/or exosomes\                          \[[@B68-ijms-21-00665]\]
                                                                                       Uneven loading into exosomes                                                                       

  Membrane integration\                 Simple and easy                                May cause clumping of exosomes\                                                                    \[[@B65-ijms-21-00665]\]
  (lipophilic fluorescent dyes)                                                        Cannot distinguish between lipid proteins and micelle\                                             
                                                                                       May cause background signals from dissociated probes\                                              
                                                                                       May cause pseudo signals even after clearance of exosomes\                                         
                                                                                       May affect the interaction of exosomes with target cells                                           

  Encapsulation by electroporation      May avoid surface modification                 May cause aggregation or fusion of exosomes                                                        \[[@B65-ijms-21-00665]\]

  Encapsulation by lipophilic agents    Simple and easy                                May cause background signals from released probes                                                  \[[@B65-ijms-21-00665]\]

  Transporter-dependent encapsulation   Simple and easy                                Depends on transporter (e.g., GLUT1)\                                                              \[[@B75-ijms-21-00665]\]
                                                                                       Un-even encapsulation\                                                                             
                                                                                       May cause background signals from released probes                                                  

  Metabolic labeling                    Covalent biding of probes by click chemistry   May change the property of cells and/or exosomes\                                                  \[[@B74-ijms-21-00665],[@B76-ijms-21-00665]\]
                                                                                       May change membrane protein functions which affect the interaction of exosomes with target cells   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-21-00665-t004_Table 4

###### 

Biodistribution of exosomes in literature.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Labeling Method                 Modality                           Nomenclature\                      Cell Source                                                     Isolation Method                                Purification after Labeling   Dose (/Head)                                 Animal Model                                        Admin.\                 Imaging Method          Tissue Distribution                                                                                           Ref.
                                                                     (Markers)                                                                                                                                                                                                                                                                         Route                                                                                                                                                         
  ------------------------------- ---------------------------------- ---------------------------------- --------------------------------------------------------------- ----------------------------------------------- ----------------------------- -------------------------------------------- --------------------------------------------------- ----------------------- ----------------------- ------------------------------------------------------------------------------------------------------------- --------------------------
  Covalent\                       RI\                                EVs                                MLP29\                                                          UC\                                             SEC\                          0.6--1.8 MBq\                                Mouse\                                              IV\                     PET                     Bladder \> liver \> thyroid \> lung \> kidney \> brain                                                        \[[@B66-ijms-21-00665]\]
  binding                         (^124I^)                                                              (murine liver-derived progenitor cell line)                     (100,000 g, 70 min)                             (Sephadex G-25)               (40--120 ng)                                 (BALB/cJRj)                                         hock                                                                                                                                                          

  Covalent binding                Fluorescence\                      Exosomes\                          Human U937\                                                     UC\                                             SEC\                          40 μg                                        Mouse\                                              IV                      IVIS                    Liver \> kidney, tumor, spleen, heart, lung, colon, brain, bladder, blood                                     \[[@B77-ijms-21-00665]\]
                                  (Cy7-NHS)                          (CD9, ALIX, TSG101)                leukemia cells                                                  (100,000 g, 2 h)                                (Sephadex G50)                                                             (BALB/c) with syngeneic CT26 colon adenocarcinoma                                                                                                                                                                 

  Covalent binding                Fluorescence\                      EVs                                *Helicobacter pylori*                                           UC (150,000 g, 3 h) and DGUC (100,000 g, 2 h)   Not disclosed                 Not disclosed                                Mouse\                                              Oral                    IVIS                    Mouse, stomach                                                                                                \[[@B78-ijms-21-00665]\]
                                  (Cy7-NHS)                                                                                                                                                                                                                                                        (C57BL/6)                                                                                                                                                                                                         

  Covalent binding                Fluorescence\                      Bacterial EVs (OMVs)               *E. coli*                                                       UC\                                             UC\                           15 μg                                        Mouse\                                              IP                      IVIS                    (3 h) liver \> kidney \> lung \> spleen \> small intestine\                                                   \[[@B79-ijms-21-00665]\]
                                  (Cy7-NHS)                                                                                                                             (150,000 g, 3 h)                                (150,000 g, 3 h)                                                           (C57BL/6 and SKH1-E)                                                                                (24 h) liver                                                                                                  

  Covalent binding                RI\                                Exosomes\                          Murine B16F10\                                                  UC\                                             SEC\                          1 × 10^11^                                   Mouse\                                              IV                      SPECT/CT                Liver \> spleen \> bone, kidney, lung                                                                         \[[@B80-ijms-21-00665]\]
                                  (^111^Indium)                      (CD81, CD9)                        melanoma                                                        (100,000 g, 90 min)                             (Sepharose CL-2B)                                                          (C57BL/6 and NSG), melanoma-bearing                                                                                                                                                                               

  Covalent binding                RI\                                Exosomes\                          Mouse MDSCs and EPCs, HEK293                                    UF (100 kDa)\                                   UF\                           350 ± 50 μCi                                 Mouse\                                              IV                      SPECT/CT                (Tumor exosomes) tumor \> liver \> lung, spleen, kidney, brain, heart\                                        \[[@B81-ijms-21-00665]\]
                                  (^131^I)                           (CD9, CD63)                                                                                        and UC\                                         (100 kDa)                                                                  (BALB/c or C57BL/J6)\                                                                               (MDSC-exosome) liver, lung, tumor \> kidney, spleen, brain, heart\                                            
                                                                                                                                                                        (100,000 g, 70 min)                                                                                                        Xenograft bearing 4T1 or AT3                                                                        (EPC-exosomes) tumor \> liver \> lung, kidney, brain, spleen, heart                                           

  Covalent binding                RI\                                EVs                                Erythrocyte                                                     UC\                                             SEC\                          15 ± 2 Mbq                                   Mouse\                                              IV                      SPECT/CT                Liver, bladder, spleen \> kidney \> lung, heart, bone                                                         \[[@B82-ijms-21-00665]\]
                                  \[^99m^Tc(CO)~3~(−H~2~O)~3~\]^+^                                                                                                      (130,000 g, 30 min)\                            (Desalting Column)                                                         (BALB/c)                                                                                                                                                                                                          
                                                                                                                                                                        and SEC                                                                                                                                                                                                                                                                                                                                      

  Metabolic labeling              Fluorescence\                      Exosomes\                          Human\                                                          ExoQuick                                        Gel filtration\               10 μg                                        Mouse, athymic\                                     IV                      IVIS                    (MCF7 exosomes) liver \> large and small intestines \> kidney, tumor, spleen, lung, muscle, blood\            \[[@B74-ijms-21-00665]\]
                                  (Cy3 or Cy5.5)                     (CD63)                             MDA-MD-231 and MCF7 breast cancer cells                                                                         (G-25)                                                                     MDA-MB-231 or MCF7 tumor bearing                                                                    (MDA-MD-231 exosomes) liver \> large and small intestines \> lung \> tumor, spleen, kidney \> muscle, blood   

  Genetic Engineering             Luminescence\                      Exosomes\                          HT29/CD63Nluc and\                                              UC\                                             NA                            NA                                           Female mouse (Balb/c-nu/nu)                         NA\                     BLI\                    Stomach, intestine                                                                                            \[[@B83-ijms-21-00665]\]
                                  (CD63-NanoLuc)                     (CD63)                             HCD116/CD63Nluc                                                 (110,000 g, 70 min)                                                                                                                                                            (SC implant of cells)   (IVIS)                                                                                                                                

  Genetic Engineering             Luminescence\                      EVs\                               CAL-62 thyroid cancer cell and MDA-MB-231 breast cancer cells   UC\                                             NA                            25 μg                                        Mouse\                                              IV                      BLI\                    62/Rluc: lung\> liver \> spleen \> kidney\                                                                    \[[@B67-ijms-21-00665]\]
                                  (Renilla Luciferase; Rluc)         (CD63, Alix)                                                                                       (100,000 g, 60 min)                                                                                                        (BALB/c, female)\                                                           (IVIS)                  62/Rluc/DiR: liver \> lung, spleen\                                                                           
                                                                                                                                                                                                                                                                                                   N = 3                                                                                               231Rluc: lung, liver \> spleen \> kidney                                                                      

  Genetic Engineering             Luminescence\                      EVs\                               HEK293T cells                                                   UC\                                             NA                            100 μg                                       Mouse\                                              IV                      BLI                     Spleen, liver \> lung, kidney, brain, heart, muscle                                                           \[[@B84-ijms-21-00665]\]
                                  (Gaussia Luciferase)               (CD63, ALIX)                                                                                       (100,000 g, 90 min)                                                                                                        (athymic nude)                                                                                                                                                                                                    

  Genetic Engineering             Luminescence\                      Exosomes                           B16-Bl6 murine melanoma cells                                   UC\                                             NA                            1 × 10^10^ RLU\                              Mouse\                                              IV                      BLI\                    Lung \> spleen \> kidney, liver, heart, brain, intestine                                                      \[[@B85-ijms-21-00665]\]
                                  (Gaussia Luciferase)                                                                                                                  (100,000 g, 1 h)                                                              (5 μg)                                       (BALB/c)                                                                    (LAS3000)                                                                                                                             

  Membrane integration            MR\                                Exosomes\                          Human UC-MSCs                                                   UC\                                             UF\                           0.015 mmol/kg                                Mouse, K7M2 (human osteosarcoma) xenograft\         IV                      MRI                     Liver, spleen \> tumor \> lung, kidney, heart, brain                                                          \[[@B86-ijms-21-00665]\]
                                  (gadolinium)                       (CD9, CD63, CD81)                                                                                  (120,000 g, 90 min)                             (10 kDa)                                                                   (NU/NU)                                                                                                                                                                                                           

  Membrane integration            Fluorescence\                      Exosomes\                          Human UC-MSCs                                                   UC\                                             Not disclosed                 5 mg/kg                                      Mouse, K7M2 (human osteosarcoma) xenograft\         IV                      LI-COR                  Spleen \> liver \> tumor, lung \> kidney, brain, heart                                                        \[[@B86-ijms-21-00665]\]
                                  (DiR)                              (CD9, CD63, CD81)                                                                                  120,000 g, 90 min)                                                                                                         (NU/NU)                                                                                                                                                                                                           

  Membrane integration            Fluorescence\                      Wnt4-exosomes                      Mouse TEP1 (primary thymic epithelial cell)                     TEI (Invitrogen)                                TEI\                          Not disclosed                                Mouse\                                              IV                      IVIS                    Thymus \> lung, liver, spleen                                                                                 \[[@B87-ijms-21-00665]\]
                                  (Dil)                                                                                                                                                                                 (pre-labeling)                                                             (BALB/c)                                                                                                                                                                                                          

  Membrane integration            Fluorescence\                      CVs\                               hCMEC/D3\                                                       UC\                                             SEC                           200 μg of lipid                              Mouse\                                              ROVS                    IVIS                    Liver \> spleen, lung \> brain                                                                                \[[@B88-ijms-21-00665]\]
                                  (DiR)                              (by sonication)                    B16                                                             (60,000 rpm, 24 h)                                                                                                         (FVB albino)                                                                                                                                                                                                      

  Membrane integration            Fluorescence (DiR)                 Exosomes\                          C2C12 murine myoblast cell                                      UC\                                             Not disclosed                 30 μg                                        Mouse\                                              IV                      IVIS                    Liver \> spleen \> lung                                                                                       \[[@B89-ijms-21-00665]\]
                                                                     (ALIX, CD63, CD81, CD9, TSG101)                                                                    (100,000 g, 1 h)                                                                                                           (C57BL/6)                                                                                                                                                                                                         

  Membrane integration            Fluorescence (DiR)                 Exosomes                           BM-MSC                                                          UC\                                             UC\                           8 × 10^9^                                    Mouse\                                              IP                      IVIS                    Liver, spleen, pancreas                                                                                       \[[@B45-ijms-21-00665]\]
                                                                                                                                                                        (100,000 g, 3 h)                                (100,000 g, ND)                                                            (C57BL/6)\                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                   Tumor vs. non tumor                                                                                                                                                                                               

  Membrane integration            Fluorescence (PKH67)               Exosomes (CD63)                    Mouse BM-MSC                                                    UF + ExoQuick                                   ExoQuick                      30 μg                                        Mouse\                                              IV                      IVIS                    (24 h) Tumor \> spleen \> kidney, liver, lung                                                                 \[[@B90-ijms-21-00665]\]
                                                                                                                                                                                                                                                                                                   (BALB/c)\                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                   TUBO tumor                                                                                                                                                                                                        

  Membrane integration            Fluorescence (DiR)                 Exosomes\                          Endothelial colony forming cell (ECFC)                          UC\                                             UC\                           20 μg                                        Male FVB mice                                       IV                      IVIS                    (4 h) kidney \> liver, heart, spleen, lung                                                                    \[[@B91-ijms-21-00665]\]
                                                                     (TSG101, CD81)                                                                                     (100,000 g, 90 min)                             (100,000 g)                                                                                                                                                                                                                                                                                  

  Membrane integration            Fluorescence (DiD)                 Exosomes\                          Murine EO771 BC cells                                           Combination of UF (100 kDa) and SEC             UC\                           20 μg\                                       Mouse\                                              IV                      IVIS\                   Lung, \> liver \> spleen, kidney \> heart \> bone marrow                                                      \[[@B92-ijms-21-00665]\]
                                                                     (TSG101, CD9, HSP70; GM130-)                                                                                                                       (100,000 g, 90 min)           (1.6 × 10^11^)                               (C57BL/6 or\                                                                organ imaging                                                                                                                         
                                                                                                                                                                                                                                                                                                   BALB/C)                                                                                                                                                                                                           

  Membrane integration            Fluorescence (DiD)                 Exosomes\                          Murine 4T1 BC cells                                             UC\                                             UC\                           20 μg\                                       Mouse\                                              IV                      IVIS\                   Lung \> liver \> kidney \> spleen, heart, bone marrow                                                         \[[@B92-ijms-21-00665]\]
                                                                     (TSG101, CD9, HSP70; GM130-)                                                                       (100,000× *g*, 90 min)                          (100,000 g, 90 min)           (1.2 × 10^11^)                               (C57BL/6 or\                                                                organ imaging                                                                                                                         
                                                                                                                                                                                                                                                                                                   BALB/C)                                                                                                                                                                                                           

  Membrane integration            Fluorescence (DiD)                 Exosomes                           Murine 67NR BC cells                                            UC\                                             UC\                           20 μg\                                       Mouse\                                              IV                      IVIS\                   Lung \> liver \> kidney \> spleen, heart, bone marrow                                                         \[[@B92-ijms-21-00665]\]
                                                                                                                                                                        (100,000× *g*, 90 min)                          (100,000 g, 90 min)           (1.2 × 10^11^)                               (C57BL/6 or\                                                                organ imaging                                                                                                                         
                                                                                                                                                                                                                                                                                                   BALB/C)                                                                                                                                                                                                           

  Membrane integration            Fluorescence (DiR)                 EVs                                Undisclosed                                                     NA                                              UC (120,000 g, 70 min) vs.\   Undisclosed                                  Mouse\                                              IV                      IVIS\                   (UC) liver \> lung, spleen \> kidney\                                                                         \[[@B93-ijms-21-00665]\]
                                                                                                                                                                                                                        UF (100 kDa)--SEC\                                                         (BALB/c)                                                                    organ imaging           (UF-SEC) liver \> spleen \> lung \> kidney                                                                    
                                                                                                                                                                                                                        (S-400)                                                                                                                                                                                                                                                                                      

  Membrane integration            Fluorescence (DiR)                 EVs\                               HEK293T cells                                                   UC\                                             NA\                           1.5 × 10^10^, 1,0 × 10^10^, 0.25 × 10^10^\   Mouse\                                              IV\                     IVIS                    \(IV\) liver \> GI-tract, spleen \> lung \> pancreas\                                                         \[[@B68-ijms-21-00665]\]
                                                                     (ALIX, TSG101)                                                                                     (110,000 g, 70 min)                             (pre-labeling before UC)      p/g BW                                       (NMRI or C57BL/6)                                   IP\                                             (IP) liver, GI-tract, pancreas \> spleen, lung\                                                               
                                                                                                                                                                                                                                                                                                                                                       SC                                              (SC) GI-tract \> liver \> pancreas, lung \> spleen                                                            

  Membrane integration            Fluorescence (DiR)                 EVs\                               DC cells                                                        UC\                                             NA\                           1.0 × 10^10^\                                Mouse\                                              IV                      IVIS                    Liver \> spleen \> GI-tract, lung \> pancreas                                                                 \[[@B68-ijms-21-00665]\]
                                                                     (ALIX, TSG101)                                                                                     (110,000 g, 70 min)                             (pre-labeling before UC)      p/g BW                                       (NMRI or C57BL/6)                                                                                                                                                                                                 

  Membrane integration            Fluorescence (DiR)                 EVs\                               C2C12 cells                                                     UC\                                             NA\                           1.0 × 10^10^\                                Mouse\                                              IV                      IVIS                    Liver \> spleen \> GI-tract \> lung \> pancreas                                                               \[[@B68-ijms-21-00665]\]
                                                                     (ALIX, TSG101)                                                                                     (110,000 g, 70 min)                             (pre-labeling before UC)      p/g BW                                       (NMRI or C57BL/6)                                                                                                                                                                                                 

  Membrane integration            Fluorescence (DiR)                 EVs\                               B16F10 cells                                                    UC\                                             NA\                           1.0 × 10^10^\                                Mouse\                                              IV                      IVIS                    Liver \> GI-tract, spleen, lungs \> pancreas                                                                  \[[@B68-ijms-21-00665]\]
                                                                     (ALIX, TSG101)                                                                                     (110,000 g, 70 min)                             (pre-labeling before UC)      p/g BW                                       (NMRI or C57BL/6)                                                                                                                                                                                                 

  Membrane integration            Fluorescence (DiR)                 Exosome\                           BMSCs                                                           UF (3 kDa)-ExoQuick-TC                          ExoQuick-TC                   500 μg                                       C57BL/KaLwRij                                       IV                      Fluobean 800            BM, spleen, liver                                                                                             \[[@B94-ijms-21-00665]\]
                                                                     (CD63,\                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                     flotillin-1)                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Membrane integration            Fluorescence (DiD)                 EVs\                               MSCs                                                            UC\                                             UC                            200 μg                                       Mouse\                                              IV                      IVIS\                   (24 h) liver \> spleen \> lung                                                                                \[[@B95-ijms-21-00665]\]
                                                                     (CD44, CD105, CD90, α5-integrin)                                                                   (100,000 g, 1 h)                                                                                                           CD1 with or without glycerol-induced AKI                                    organ imaging                                                                                                                         

  Encapsulation                   RI\                                Exosome mimetics                   Rat RBCs                                                        UC\                                             Centrifugation\               37 Mbq                                       Mouse\                                              IV                      Gamma camera imaging    Liver, spleen, kidney \> thyroid, stomach, lung, blood, intestine \> heart, muscle, bone                      \[[@B65-ijms-21-00665]\]
                                  ^99m^Tc                                                                                                                               (100,000 g, 1 h) + DGUC                         (not disclosed in detail)                                                  (C57BL/6, male)                                                                                                                                                                                                   

  Encapsulation                   MR\                                Exosomes\                          Human MSCs                                                      UC\                                             UC\                           2.8 × 10^9^                                  Mouse\                                              IV\                     CT                      \(IV\) lung, liver \> spleen \> kidney, brain, blood\                                                         \[[@B96-ijms-21-00665]\]
                                  gold nanoparticles                 (CD9)                                                                                              (100,000 g, 70 min)                             (100,000 g, 2 h)                                                           (C57bl/6, male)                                     IN                                              (IN) lung \> spleen \> kidney, brain, blood, liver                                                            

  Encapsulation                   RI\                                Exosome mimetic                    RAW264.7                                                        DGUC\                                           SEC\                          7.4--14.8 Mbq\                               Mouse\                                              IV                      SPECT/CT                (5 h) liver \> kidney \> spleen \> intestine \> lung, heart, stomach, heart \> bone, muscle, blood            \[[@B97-ijms-21-00665]\]
                                  ^99m^Tc-HMPAO                                                                                                                         (100,000 g, 2 h)                                (MW3000)                      (29--64 μg)                                  (BALB/c)                                                                                                                                                                                                          

  Encapsulation by transfection   MR\                                Exosomes\                          MDA-MB-231                                                      ExoQuick                                        NA                            100 μg                                       Mouse                                               IV                      MPI\                    Liver                                                                                                         \[[@B75-ijms-21-00665]\]
                                  SPIO                               (CD9, CD63)                                                                                                                                                                                                                                                                                               CT                                                                                                                                    

  Encapsulation by Sonication     Fluorescence\                      Tumor targeting EVs                RAW264.7                                                        UC\                                             UC\                           10 mg/kg                                     Mouse\                                              IV                      Image Station 4000 MM   Tumor \> liver \> lung, kidney, spleen, brain, heart                                                          \[[@B76-ijms-21-00665]\]
                                  Chlorin e6 (Ce6)                                                                                                                      (100,000 g, 70 min)                             (100,000 g, 70 min)                                                        (BALB/c nu/nu)\                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                   with HCT116 tumor                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations**: AKI, acute kidney injury; BC, breast cancer; BLI, bioluminescence imaging; BMSC, bone marrow stromal cell; BW, body weight; CV, cellular vesicle; CT, computed tomography; DGUC, density-gradient ultracentrifugation; EPCs, endothelial progenitor cells; FI, fluorescence intensity; FP, fluorescence protein; GNP, gold nanoparticle; ICP-MS, inductively coupled plasma mass spectroscopy; IN, intranasal; IV, intravenous; IP, intraperitoneal; MDSCs: myeloid derived suppressor cells; MPI, magnetic particle imaging; MR, magnetic resonance; MRI, magnetic resonance imaging; MSC, mesenchymal stem/stromal cell; NA, not applicable; ND, not determined; NR, nuclear imaging; OMV, outer membrane vesicle; RI, radioisotope; RLU, relative luminescence unit; ROVS, retro-orbital venous sinus; SC, subcutaneous; SEC, size exclusion chromatography; SPECT, single-photon emission computed tomography; SPIO, superparamagnetic iron oxide; TEI, total exosome isolation reagent; UC, ultracentrifugation; UC-MSC, umbilical cord MSC; UF, ultrafiltration.
